EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Model‐Informed Abatacept Dose Recommendation in Pediatric Patients With Acute Graft Versus Host Disease

Rui Zhong iD, Kelly Maxwell, Julie Passarell, Bindu Murthy, Urvi Aras, Daphne Williams

The Journal of Clinical Pharmacology · 2026

DOI: 10.1002/jcph.70156 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Rui Zhong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Hauptthemen laut MEDLINE: Abatacept, Graft vs Host Disease, Models, Biological, Immunosuppressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol Myers Squibb Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study uses a population pharmacokinetic (PPK) approach to provide abatacept dosing recommendations in pediatric patients 2 to < 6 years of age receiving unrelated donor hematopoietic stem cell transplantation (HSCT) due to hematologic malignancies (HMs), for the prophylaxis of acute graft‐versus‐host disease (aGVHD). An intermediate PPK model was developed and refined to include data from 904 patients aged 2–17 years with juvenile idiopathic arthritis administered with subcutaneous abatacept. Then, PK simulations were performed using the final PPK model for virtual pediatric patients aged 2 to < 6 years administered with either intravenous abatacept, fixed abatacept doses, or loading doses followed by maintenance dosing. The final model characterized abatacept exposure well using a linear, two‐compartment model including absorption parameters (KA and F1), and generated parameter estimates comparable to previously published models. Further simulations of abatacept exposure in 10,000 virtual patients aged 2 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AbataceptGraft vs Host DiseaseModels, BiologicalImmunosuppressive AgentsHumansChildChild, PreschoolAdolescentHematopoietic Stem Cell TransplantationFemaleMaleDose-Response Relationship, DrugHematologic NeoplasmsAcute DiseaseArthritis, Juvenile

Stichwörter der Autor:innen

abataceptgraft‐versus‐host diseasepediatric dose selectionpopulation pharmacokinetics

Substanzen

AbataceptImmunosuppressive Agents

Autor:innen und Institutionen

  • Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Lawrenceville, NJ, USA.
  • Clinical Pharmacology & Pharmacometrics, Simulations Plus, NC, USA.

ORCID-Profile: Rui Zhong

Förderung

  • Bristol Myers Squibb Company

Zitieren

APA

Zhong, R., Maxwell, K., Passarell, J., Murthy, B., Aras, U., & Williams, D. (2026). Model‐Informed Abatacept Dose Recommendation in Pediatric Patients With Acute Graft Versus Host Disease. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70156

Vancouver

Zhong R, Maxwell K, Passarell J, Murthy B, Aras U, Williams D. Model‐Informed Abatacept Dose Recommendation in Pediatric Patients With Acute Graft Versus Host Disease. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70156

BibTeX
@article{Zhong2026,
  author = {Zhong, Rui and Maxwell, Kelly and Passarell, Julie and Murthy, Bindu and Aras, Urvi and Williams, Daphne},
  title = {Model‐Informed Abatacept Dose Recommendation in Pediatric Patients With Acute Graft Versus Host Disease},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/jcph.70156}
}
Kostenlos starten →